Your browser doesn't support javascript.
loading
Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus.
Brüggen, M-C; Le, S T; Walsh, S; Toussi, A; de Prost, N; Ranki, A; Didona, B; Colin, A; Horváth, B; Brezinova, E; Milpied, B; Moss, C; Bodemer, C; Meyersburg, D; Salavastru, C; Tiplica, G-S; Howard, E; Bequignon, E; Bouwes Bavinck, J N; Newman, J; Gueudry, J; Nägeli, M; Zaghbib, K; Pallesen, K; Bygum, A; Joly, P; Wolkenstein, P; Chua, S-L; Le Floch, R; Shear, N H; Chu, C-Y; Hama, N; Abe, R; Chung, W-H; Shiohara, T; Ardern-Jones, M; Romanelli, P; Phillips, E J; Stern, R S; Cotliar, J; Micheletti, R G; Brassard, A; Schulz, J T; Dodiuk-Gad, R P; Dominguez, A R; Paller, A S; Seminario-Vidal, L; Mostaghimi, A; Noe, M H; Worswick, S.
Afiliación
  • Brüggen MC; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Le ST; Faculty of Medicine, University of Zurich, Zurich, Switzerland.
  • Walsh S; Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
  • Toussi A; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • de Prost N; Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
  • Ranki A; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Didona B; Department of Dermatology, King's College Hospital, London, UK.
  • Colin A; Department of Dermatology, University of California, Davis, Sacramento, CA, USA.
  • Horváth B; Intensive Care Unit, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Brezinova E; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Milpied B; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Moss C; Department of Skin and Allergic Diseases, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
  • Bodemer C; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Meyersburg D; First Dermatology Division, Institute Dermopatico dell'Immacolata (I.D.I.) - IRCCS, Via Monti di Creta 104, Rome, 00167, Italy.
  • Salavastru C; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Tiplica GS; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Howard E; Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Bequignon E; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Bouwes Bavinck JN; Department of Dermatology, Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Newman J; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Gueudry J; Department of Dermatovenereology, St Ann's University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
  • Nägeli M; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Zaghbib K; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Pallesen K; Department of Dermatology, CHU Bordeaux, Bordeaux, France.
  • Bygum A; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Joly P; Birmingham Children's Hospital and University of Birmingham, Birmingham, UK.
  • Wolkenstein P; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Chua SL; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Le Floch R; Department of Dermatology, AP-HP, Necker Hospital, Paris, France.
  • Shear NH; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Chu CY; Department of Dermatology and Allergology, University Hospital Salzburg of the Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Hama N; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Abe R; Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Chung WH; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Shiohara T; Department of Dermatology II, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Ardern-Jones M; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Romanelli P; Birmingham Children's Hospital and University of Birmingham, Birmingham, UK.
  • Phillips EJ; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Stern RS; Department of Otorhinolaryngology and Head and Neck Surgery, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Cotliar J; Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Micheletti RG; Macmillan Skin Cancer CNS, Normanby Building, Denmark Hill, London, UK.
  • Brassard A; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Schulz JT; Ophthalmology Department, Hospital Charles Nicolle, EA7510, UFR Santé, Rouen University, Rouen, France.
  • Dodiuk-Gad RP; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Dominguez AR; Toxic Bullous Dermatoses TOXIBUL Reference Centre, Filière FIMARAD, AP-HP, Henri Mondor Hospital, Créteil, France.
  • Paller AS; Department of Psychiatry, AP-HP, Henri Mondor-Albert Chenevier Hospitals, Cr, France.
  • Seminario-Vidal L; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Mostaghimi A; Department of Dermatology, Aarhus University Hospital, Palle Juul-Jensens, Aarhus, Denmark.
  • Noe MH; ToxiTEN Group, European Reference Network for Rare Skin Diseases (ERN-skin), Paris, France.
  • Worswick S; Clinical Institute, University of Southern Denmark, Department of Clinical Genetics, Odense University Hospital, Odense, Denmark.
Br J Dermatol ; 185(3): 616-626, 2021 09.
Article en En | MEDLINE | ID: mdl-33657677
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Stevens-Johnson Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Child / Humans Idioma: En Revista: Br J Dermatol Año: 2021 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Stevens-Johnson Tipo de estudio: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research Límite: Adult / Child / Humans Idioma: En Revista: Br J Dermatol Año: 2021 Tipo del documento: Article País de afiliación: Suiza